Clinical trial · Observational
AFP - L3% and DCP as Screening Marker for a Hepatocellular Carcinoma in Patients With Cirrhosis of the Liver
AFP - L3% and DCP as Screening Marker for a Hepatocellular Carcinoma in Patients With Cirrhosis of the Liver- am Multicenter HCC- Surveillance Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Hepatocellular carcinoma (HCC) is one of the tumors with a rising incidence worldwide. The aim of this trial is to improve the detection of early HCC nodules in the liver. At the moment screening for HCC in patients with liver cirrhosis is performed by ultrasound and measurement of alpha- fetoprotein (AFP). In this trail the tumor markers AFP- L3 (a subfraction of AFP) and Des-y- carboxyprothromib (DCP) are measured in addition in order to receive information about the course of these markers before the detection of a HCC nodule.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cirrhosis | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- patients with liver cirrhosis
Primary outcomes (1)
- measure
- development of HCC
- timeFrame
- up to 3 years
- description
- all patients with liver cirrhosis in this clinical trial are examined every 6 months performing ultrasound and measurement of AFP, AFP-L3% and DCP
Secondary outcomes (2)
- measure
- comparison of these liver cancer markers (AFP, AFP-L3% and DCP) between men and women
- timeFrame
- baseline
- description
- The levels of these liver cancer markers are compared in men and women and it will be evaluated if one marker is superior than the others in men or women.
- measure
- comparison of these liver cancer markers (AFP, AFP-L3% and DCP) between different etiologies
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * age between 18 and 80 * cirrhosis of the liver confirmed by ultrasound or other imaging techniques (MRI, CT) or biopsy * at the time of enrollment: no HCC- suspected lesion detectable in the liver Exclusion Criteria: * liver tumors or metastasis or tumor of unknown origin
References
Publications (0)
Data not yet available